CN102631327A - 一种奥美拉唑肠溶微丸及其制备方法 - Google Patents
一种奥美拉唑肠溶微丸及其制备方法 Download PDFInfo
- Publication number
- CN102631327A CN102631327A CN2012101480632A CN201210148063A CN102631327A CN 102631327 A CN102631327 A CN 102631327A CN 2012101480632 A CN2012101480632 A CN 2012101480632A CN 201210148063 A CN201210148063 A CN 201210148063A CN 102631327 A CN102631327 A CN 102631327A
- Authority
- CN
- China
- Prior art keywords
- coating
- enteric
- omeprazole
- hydroxypropyl emthylcellulose
- sprayed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 title claims abstract description 98
- 229960000381 omeprazole Drugs 0.000 title claims abstract description 84
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- 239000008188 pellet Substances 0.000 title abstract description 7
- 238000000576 coating method Methods 0.000 claims abstract description 144
- 239000011248 coating agent Substances 0.000 claims abstract description 142
- -1 diacetyl monoglyceride Chemical compound 0.000 claims abstract description 89
- 239000002702 enteric coating Substances 0.000 claims abstract description 31
- 238000009505 enteric coating Methods 0.000 claims abstract description 31
- 239000004925 Acrylic resin Substances 0.000 claims abstract description 21
- 229920000178 Acrylic resin Polymers 0.000 claims abstract description 21
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 20
- 229930195725 Mannitol Natural products 0.000 claims abstract description 20
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000000594 mannitol Substances 0.000 claims abstract description 20
- 235000010355 mannitol Nutrition 0.000 claims abstract description 20
- 102220570135 Histone PARylation factor 1_L30D_mutation Human genes 0.000 claims abstract description 19
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims abstract description 17
- 150000002148 esters Chemical class 0.000 claims abstract description 17
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 17
- 239000001069 triethyl citrate Substances 0.000 claims abstract description 17
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims abstract description 17
- 235000013769 triethyl citrate Nutrition 0.000 claims abstract description 17
- 229940008099 dimethicone Drugs 0.000 claims abstract description 10
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims abstract description 10
- 239000004205 dimethyl polysiloxane Substances 0.000 claims abstract description 10
- 239000000839 emulsion Substances 0.000 claims abstract description 10
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims abstract description 10
- 239000006187 pill Substances 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 41
- 239000007864 aqueous solution Substances 0.000 claims description 33
- 239000002775 capsule Substances 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 24
- 238000001035 drying Methods 0.000 claims description 22
- 239000000843 powder Substances 0.000 claims description 22
- 239000011241 protective layer Substances 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 239000011812 mixed powder Substances 0.000 claims description 17
- 238000005453 pelletization Methods 0.000 claims description 17
- 230000008569 process Effects 0.000 claims description 17
- 239000007921 spray Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000000725 suspension Substances 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 13
- 238000005303 weighing Methods 0.000 claims description 11
- 239000011805 ball Substances 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 8
- 229920000053 polysorbate 80 Polymers 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 5
- 230000004927 fusion Effects 0.000 claims description 5
- 239000002253 acid Substances 0.000 abstract description 11
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 3
- 239000011253 protective coating Substances 0.000 abstract 2
- 238000009776 industrial production Methods 0.000 abstract 1
- 229950008882 polysorbate Drugs 0.000 abstract 1
- 229920000136 polysorbate Polymers 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 14
- 229930006000 Sucrose Natural products 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 229960004793 sucrose Drugs 0.000 description 14
- 239000010410 layer Substances 0.000 description 12
- 239000005720 sucrose Substances 0.000 description 12
- 238000007789 sealing Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 239000008213 purified water Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 206010017758 gastric cancer Diseases 0.000 description 6
- 201000011549 stomach cancer Diseases 0.000 description 6
- 210000004211 gastric acid Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000008469 Peptic Ulcer Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 208000011906 peptic ulcer disease Diseases 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000012928 buffer substance Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100021022 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 150000004008 N-nitroso compounds Chemical class 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- OYCDTPQIKJZGBS-UHFFFAOYSA-N P(O)(O)(O)=O.[O] Chemical compound P(O)(O)(O)=O.[O] OYCDTPQIKJZGBS-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229950002342 bisfentidine Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- FXJAOWANXXJWGJ-UHFFFAOYSA-N n-[4-(2-methyl-1h-imidazol-5-yl)phenyl]-n'-propan-2-ylmethanimidamide Chemical compound C1=CC(NC=NC(C)C)=CC=C1C1=CN=C(C)N1 FXJAOWANXXJWGJ-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940080133 omeprazole 20 mg Drugs 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 239000001038 titanium pigment Substances 0.000 description 1
- 238000004078 waterproofing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201210148063 CN102631327B (zh) | 2012-05-14 | 2012-05-14 | 一种奥美拉唑肠溶微丸及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201210148063 CN102631327B (zh) | 2012-05-14 | 2012-05-14 | 一种奥美拉唑肠溶微丸及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102631327A true CN102631327A (zh) | 2012-08-15 |
CN102631327B CN102631327B (zh) | 2013-08-28 |
Family
ID=46616011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201210148063 Active CN102631327B (zh) | 2012-05-14 | 2012-05-14 | 一种奥美拉唑肠溶微丸及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102631327B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103919734A (zh) * | 2014-04-24 | 2014-07-16 | 海南葫芦娃制药有限公司 | 头孢泊肟酯微丸、胶囊及其制备方法 |
CN104013580A (zh) * | 2014-06-13 | 2014-09-03 | 海南葫芦娃制药有限公司 | 兰索拉唑微丸、胶囊及其制备方法 |
CN105213350A (zh) * | 2015-11-11 | 2016-01-06 | 上海爱的发制药有限公司 | 盐酸奥昔布宁缓释胶囊及其制备方法 |
CN114099471A (zh) * | 2021-11-03 | 2022-03-01 | 海南海灵化学制药有限公司 | 一种奥美拉唑肠溶微丸及其制备工艺 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000027366A1 (en) * | 1998-11-05 | 2000-05-18 | Astrazeneca Ab | Pharmaceutical formulation comprising omeprazole |
EP1416922A1 (en) * | 2001-07-16 | 2004-05-12 | AstraZeneca AB | Pharmaceutical formulation comprising a proton pump inhibitor and antacids |
CN1985822A (zh) * | 2006-12-14 | 2007-06-27 | 湖南康普制药有限公司 | 奥美拉唑肠溶微丸及其制备方法 |
CN101036633A (zh) * | 2007-04-28 | 2007-09-19 | 杭州民生药业集团有限公司 | 一种奥美拉唑肠溶微丸胶囊及其制备方法 |
-
2012
- 2012-05-14 CN CN 201210148063 patent/CN102631327B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000027366A1 (en) * | 1998-11-05 | 2000-05-18 | Astrazeneca Ab | Pharmaceutical formulation comprising omeprazole |
EP1416922A1 (en) * | 2001-07-16 | 2004-05-12 | AstraZeneca AB | Pharmaceutical formulation comprising a proton pump inhibitor and antacids |
CN1985822A (zh) * | 2006-12-14 | 2007-06-27 | 湖南康普制药有限公司 | 奥美拉唑肠溶微丸及其制备方法 |
CN101036633A (zh) * | 2007-04-28 | 2007-09-19 | 杭州民生药业集团有限公司 | 一种奥美拉唑肠溶微丸胶囊及其制备方法 |
Non-Patent Citations (1)
Title |
---|
胡海洋等: "奥美拉唑肠溶微丸的制备及其处方优化", 《中国药学杂志》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103919734A (zh) * | 2014-04-24 | 2014-07-16 | 海南葫芦娃制药有限公司 | 头孢泊肟酯微丸、胶囊及其制备方法 |
CN104013580A (zh) * | 2014-06-13 | 2014-09-03 | 海南葫芦娃制药有限公司 | 兰索拉唑微丸、胶囊及其制备方法 |
CN104013580B (zh) * | 2014-06-13 | 2016-08-24 | 海南葫芦娃药业集团股份有限公司 | 兰索拉唑微丸、胶囊及其制备方法 |
CN105213350A (zh) * | 2015-11-11 | 2016-01-06 | 上海爱的发制药有限公司 | 盐酸奥昔布宁缓释胶囊及其制备方法 |
CN105213350B (zh) * | 2015-11-11 | 2018-11-30 | 上海爱的发制药有限公司 | 盐酸奥昔布宁缓释胶囊及其制备方法 |
CN114099471A (zh) * | 2021-11-03 | 2022-03-01 | 海南海灵化学制药有限公司 | 一种奥美拉唑肠溶微丸及其制备工艺 |
CN114099471B (zh) * | 2021-11-03 | 2023-01-06 | 海南海灵化学制药有限公司 | 一种奥美拉唑肠溶微丸及其制备工艺 |
Also Published As
Publication number | Publication date |
---|---|
CN102631327B (zh) | 2013-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100490790C (zh) | 一种奥美拉唑肠溶微丸胶囊及其制备方法 | |
FI90393B (fi) | Menetelmä oraalisen, farmaseuttisen valmisteen valmistamiseksi, joka on pysyvä värin muuttumista vastaan | |
CN101596165B (zh) | 泮托拉唑钠肠溶微丸 | |
CN102119927B (zh) | 一种质子泵抑制剂的肠溶微丸制剂及其制备方法 | |
CA2342209A1 (en) | Omeprazole formulation | |
SA97170553B1 (ar) | اشكال معايرة جرعات صيدلانية تعطى بالفم تتضمن مثبط مضخة البروتون proton pump inhibitor وعامل مضاد للحموضة او الجينات alginate | |
CN104414978B (zh) | 一种含有埃索美拉唑镁的肠溶微丸 | |
SA95160091B1 (ar) | صيغة i لجرعة اقراص متعددة الوحدات | |
CN102552159B (zh) | 雷贝拉唑钠肠溶微丸及其制备方法 | |
CN103356489B (zh) | 一种质子泵抑制剂肠溶微丸及其制剂、制备方法 | |
CN102940611B (zh) | 一种含有埃索美拉唑镁的肠溶片剂 | |
CN104922086A (zh) | 一种质子泵抑制剂肠溶片的制备方法 | |
CN102631327B (zh) | 一种奥美拉唑肠溶微丸及其制备方法 | |
CN105125517A (zh) | 埃索美拉唑镁肠溶微丸胶囊及其制备方法 | |
CN101428005A (zh) | 泮托拉唑及其钠盐肠溶缓释微丸制剂 | |
CN102552256A (zh) | 一种艾普拉唑肠溶胶囊及其制备方法 | |
CN103550188B (zh) | 兰索拉唑肠溶微丸胶囊及其制备方法 | |
CN105106168A (zh) | 一种埃索美拉唑镁肠胶囊及其制备方法 | |
CN108371657A (zh) | 一种埃索美拉唑镁肠溶微丸的制备方法 | |
CN102805735A (zh) | 一种埃索美拉唑肠溶微丸片及其制备方法 | |
CN1321642C (zh) | 泮托拉唑钠肠溶微丸 | |
JP7541617B2 (ja) | 腸溶性ペレット及びその製造方法並びにそれを含む製剤 | |
CN102223879A (zh) | 制备活性组分颗粒的新方法及所获得的颗粒 | |
CN1961868A (zh) | 一种酸敏感型药物的快速崩解片剂 | |
CN203677566U (zh) | 一种用于治疗幽门螺杆菌的双层片 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 570216, East B District, No. 6, Haikou Free Trade Zone, No. 168 Nanhai Road, Hainan, Haikou Applicant after: HAINAN GOURD DOLL PHARMACEUTICAL Co.,Ltd. Address before: 570216, East B District, No. 6, Haikou Free Trade Zone, No. 168 Nanhai Road, Hainan, Haikou Applicant before: HAINAN XINZHONGZHENG PHARMACEUTICAL Co.,Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: HAINAN XINZHONGZHENG PHARMACEUTICAL CO., LTD. TO: HAINAN GOURD DOLL PHARMACEUTICAL CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 570216, East B District, No. 6, Haikou Free Trade Zone, No. 168 Nanhai Road, Hainan, Haikou Patentee after: HAINAN HULUWA PHARMACEUTICAL GROUP Co.,Ltd. Address before: 570216, East B District, No. 6, Haikou Free Trade Zone, No. 168 Nanhai Road, Hainan, Haikou Patentee before: HAINAN GOURD DOLL PHARMACEUTICAL Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Omeprazole enteric coated pellets and its preparation method Effective date of registration: 20200821 Granted publication date: 20130828 Pledgee: Bank of Communications Ltd. Hainan branch Pledgor: HAINAN HULUWA PHARMACEUTICAL GROUP Co.,Ltd. Registration number: Y2020980005271 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230328 Granted publication date: 20130828 Pledgee: Bank of Communications Ltd. Hainan branch Pledgor: HAINAN HULUWA PHARMACEUTICAL GROUP Co.,Ltd. Registration number: Y2020980005271 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |